TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-21
DOI
10.1007/s00262-020-02549-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
- (2019) Yuxue Jiang et al. Journal for ImmunoTherapy of Cancer
- Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
- (2019) Joe Yeong et al. Journal for ImmunoTherapy of Cancer
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study
- (2019) Aurelia Noske et al. EUROPEAN JOURNAL OF CANCER
- Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer
- (2018) Seo Hee Choi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer
- (2018) Xinyu Ren et al. CANCER BIOLOGY & THERAPY
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Hot Spot and Whole-Tumor Enumeration of CD8 + Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer
- (2018) Patrick J. McIntire et al. Clinical Breast Cancer
- TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-κB pathway
- (2018) Jun Wang et al. Scientific Reports
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Hotspot enumeration of CD8+ tumor infiltrating lymphocyte using digital image analysis in triple negative breast Cancer yields consistent results
- (2018) Patrick J. McIntire et al. HUMAN PATHOLOGY
- Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome
- (2018) H Torrey et al. LEUKEMIA
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
- (2017) NiJiati AiErken et al. International Journal of Biological Sciences
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- TNFR2: A Novel Target for Cancer Immunotherapy
- (2017) Éva S. Vanamee et al. TRENDS IN MOLECULAR MEDICINE
- The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease
- (2017) Gero Brockhoff et al. Oncotarget
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression
- (2016) Yichun Qiao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
- (2016) Geoffrey S. Williams et al. Oncotarget
- Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth
- (2016) H H Gari et al. Oncogenesis
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
- (2015) Fan Yan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases
- (2015) B. Ham et al. CANCER RESEARCH
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion
- (2015) Li-Yuan Chang et al. OncoImmunology
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells
- (2014) X. Chen et al. JOURNAL OF IMMUNOLOGY
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment
- (2013) Chindu Govindaraj et al. CLINICAL IMMUNOLOGY
- TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment
- (2013) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Prognostic impact of FOXP3 expression in triple-negative breast cancer
- (2012) Soohyeon Lee et al. ACTA ONCOLOGICA
- Molecular insights on basal-like breast cancer
- (2012) Mev Dominguez Valentin et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
- (2012) N R West et al. BRITISH JOURNAL OF CANCER
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- TNF inhibitor suppresses bone metastasis in a breast cancer cell line
- (2011) Takahiko Hamaguchi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+regulatory T cells in human peripheral blood
- (2010) Xin Chen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells
- (2010) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
- (2008) S. Ladoire et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started